Total Payments
$271,622
2024 Payments
$47,109
Companies
36
Transactions
568
Medicare Patients
1,903
Medicare Billing
$362,393
Payment Breakdown by Category
Other$224,913 (82.8%)
Travel$29,583 (10.9%)
Food & Beverage$16,082 (5.9%)
Consulting$1,000 (0.4%)
Education$44.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $191,783 | 121 | 70.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $33,130 | 11 | 12.2% |
| Travel and Lodging | $29,583 | 77 | 10.9% |
| Food and Beverage | $16,082 | 353 | 5.9% |
| Consulting Fee | $1,000 | 2 | 0.4% |
| Education | $44.26 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $176,190 | 207 | $0 (2024) |
| Dexcom, Inc. | $41,488 | 38 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $29,006 | 55 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $13,187 | 37 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $6,394 | 19 | $0 (2024) |
| IBSA Pharma Inc. | $1,580 | 8 | $0 (2024) |
| Lilly USA, LLC | $818.96 | 59 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $441.35 | 25 | $0 (2024) |
| Amgen Inc. | $348.24 | 20 | $0 (2024) |
| Abbott Laboratories | $313.10 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,109 | 160 | Novo Nordisk Inc ($19,861) |
| 2023 | $31,817 | 102 | Dexcom, Inc. ($22,284) |
| 2022 | $41,961 | 47 | Novo Nordisk Inc ($39,961) |
| 2021 | $44,745 | 43 | Novo Nordisk Inc ($44,466) |
| 2020 | $13,950 | 35 | Novo Nordisk Inc ($8,854) |
| 2019 | $23,523 | 67 | Novo Nordisk Inc ($14,788) |
| 2018 | $26,124 | 57 | Novo Nordisk Inc ($19,202) |
| 2017 | $42,393 | 57 | Novo Nordisk Inc ($23,112) |
All Payment Transactions
568 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $26.03 | General |
| Category: Diabetes | ||||||
| 12/18/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $27.38 | General |
| Category: Durable Pump | ||||||
| 12/18/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $17.03 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | Ultragenyx Pharmaceutical Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: XLH Metabolic Bone Disorder | ||||||
| 12/10/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/06/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,915.00 | General |
| Category: Endocrinology | ||||||
| 12/06/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Food and Beverage | In-kind items and services | $28.93 | General |
| Category: Endocrinology | ||||||
| 12/05/2024 | RECORDATI_RARE_DISEASES_INC. | SIGNIFOR LAR (Drug), ISTURISA | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: ENDOCRINE AGENT | ||||||
| 12/04/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Diabetes | ||||||
| 12/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Obesity | ||||||
| 12/03/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: NEUROSCIENCE | ||||||
| 11/26/2024 | Novo Nordisk Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| 11/25/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Diabetes Care | ||||||
| 11/25/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $1.00 | General |
| Category: Diabetes Care | ||||||
| 11/22/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $2,681.00 | General |
| Category: Endocrinology | ||||||
| 11/18/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: VACCINES | ||||||
| 11/15/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Food and Beverage | In-kind items and services | $123.34 | General |
| Category: Endocrinology | ||||||
| 11/14/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,820.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/14/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Travel and Lodging | In-kind items and services | $1,207.64 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/14/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/14/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $26.26 | General |
| Category: Rare Disease | ||||||
| 11/13/2024 | Dexcom, Inc. | DEXCOM G7 GSS (161) (Medical Supply) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,915.00 | General |
| Category: Endocrinology | ||||||
| 11/12/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: Endocrinology | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/05/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: Inflammation/Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 396 | 2,343 | $189,450 | $86,787 |
| 2022 | 8 | 482 | 2,380 | $192,862 | $88,380 |
| 2021 | 7 | 481 | 3,031 | $218,656 | $99,373 |
| 2020 | 9 | 544 | 3,347 | $224,097 | $87,853 |
Total Patients
1,903
Total Services
11,101
Medicare Billing
$362,393
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 221 | 381 | $107,442 | $47,429 | 44.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 19 | 1,680 | $59,220 | $30,801 | 52.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 84 | 192 | $13,632 | $4,927 | 36.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 21 | 25 | $5,225 | $2,025 | 38.8% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 11 | 11 | $1,705 | $833.91 | 48.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 28 | 42 | $1,890 | $441.20 | 23.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 12 | 12 | $336.00 | $329.28 | 98.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 210 | 385 | $108,570 | $49,211 | 45.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 22 | 1,620 | $57,105 | $27,611 | 48.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 81 | 153 | $10,863 | $4,107 | 37.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 34 | $7,106 | $2,986 | 42.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 65 | 104 | $4,368 | $1,767 | 40.5% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 23 | 23 | $2,530 | $1,616 | 63.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 25 | 25 | $700.00 | $686.00 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 28 | 36 | $1,620 | $396.32 | 24.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 220 | 405 | $114,210 | $52,080 | 45.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 27 | 2,283 | $80,476 | $37,059 | 46.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 35 | 48 | $10,032 | $4,000 | 39.9% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 103 | 183 | $7,669 | $3,037 | 39.6% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 32 | 32 | $3,264 | $2,126 | 65.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 35 | 35 | $980.00 | $578.20 | 59.0% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 29 | 45 | $2,025 | $494.12 | 24.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 26 | 2,582 | $91,016 | $39,980 | 43.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 211 | 349 | $98,418 | $34,319 | 34.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 56 | 72 | $15,048 | $5,671 | 37.7% |
About Dr. David Di Cesar, M.D
Dr. David Di Cesar, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in East Syracuse, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2008. The National Provider Identifier (NPI) number assigned to this provider is 1689837734.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Di Cesar, M.D has received a total of $271,622 in payments from pharmaceutical and medical device companies, with $47,109 received in 2024. These payments were reported across 568 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($191,783).
As a Medicare-enrolled provider, Di Cesar has provided services to 1,903 Medicare beneficiaries, totaling 11,101 services with total Medicare billing of $362,393. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location East Syracuse, NY
- Active Since 07/09/2008
- Last Updated 09/02/2025
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1689837734
Products in Payments
- Ozempic (Drug) $61,750
- DEXCOM G7 GSS (161) (Medical Supply) $41,427
- INVOKANA (Drug) $29,006
- RYBELSUS (Drug) $27,490
- Rybelsus (Drug) $24,686
- Victoza (Drug) $14,609
- Tresiba (Drug) $10,339
- TZIELD (Biological) $6,197
- FARXIGA (Drug) $4,660
- BYDUREON (Drug) $1,721
- Tirosint (Drug) $1,580
- JARDIANCE (Drug) $615.12
- MOUNJARO (Drug) $398.01
- TOUJEO (Drug) $370.73
- Xultophy (Drug) $260.00
- MINIMED 780G (Device) $246.07
- LEQVIO (Drug) $220.91
- TRADJENTA (Drug) $199.94
- SOLIQUA (Drug) $188.84
- FREESTYLE LIBRE 3 (Device) $177.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.